Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of alirocumab in APOE*3Leiden.CETP mice. Mice receive...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kühnast, Susan, van der Hoorn, José W. A., Pieterman, Elsbet J., van den Hoek, Anita M., Sasiela, William J., Gusarova, Viktoria, Peyman, Anusch, Schäfer, Hans-Ludwig, Schwahn, Uwe, Jukema, J. Wouter, Princen, Hans M. G.
Formato: Artigo
Idioma:Inglês
Publicado: The American Society for Biochemistry and Molecular Biology 2014
Assuntos:
Research Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4174003/
https://ncbi.nlm.nih.gov/pubmed/25139399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M051326
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares